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ABSTRACT 
Background: Although lower levels of vitamin D have been related to poor cognitive 
functioning and dementia in older adults, evidence from longitudinal investigations is 
inconsistent. The objective of this study was to determine whether 25-hydroxyvitamin D 
[25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels are associated with cognitive 
decline in ageing men.  
Methods: The European Male Ageing Study (EMAS) followed 3,369 men aged 40 to 79 over 
4.4 years. 25(OH)D levels at baseline were measured by radioimmunoassay and 1,25(OH)2D 
levels were obtained with liquid chromatography-tandem mass spectrometry. Cognitive 
functioning at baseline and follow-up was assessed using the Rey-Osterrieth Complex Figure, 
Camden Topographical Recognition Memory, and the Digit Symbol Substitution Test. 
Results: A total of 2,430 men with a mean (SD) age of 59.0 (10.6) were included in the 
analyses. At baseline the mean 25(OH)D concentration was 64.6 (31.5) nmol/l, and mean 
1,25(OH)2D level was 59.6 (16.6) pmol/l. In age-adjusted linear regression models, high 
25(OH)D concentrations were associated with a smaller decline on the DSST (β = 0.007, p = 
0.020). Men with insufficient 25(OH)D levels (<50 nmol/l) showed a greater decline on the 
CTRM compared to men with sufficient (≥75 nmol/l) levels (β = -0.41, p = 0.035). However, 
these associations disappeared after adjusting for confounders such as depression, BMI, and 
co-morbidities. There was no indication of a relationship between 1,25(OH)2D and cognitive 
decline.  
Conclusion: We found no evidence for an association between 25(OH)D or 1,25(OH)2D 
levels and cognitive decline over 4.4 years in this sample of middle-aged and elderly 
European men. 
Target journal: Journal of Neurology, Neurosurgery and Psychiatry  
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INTRODUCTION  
Vitamin D inadequacy is a common problem in Europe and the United States, with 
prevalence estimates increasing with age and ranging from 40-100% in the community-
dwelling elderly population[1]. Low vitamin D levels have been reported to be associated 
with various negative health outcomes, including osteomalacia, cancer, hypertension, and 
diabetes[2]. Recently, vitamin D has been recognized as a neuroactive steroid, and as such can 
potentially influence cognitive functioning and decline[3]. The physiological plausibility of 
this relationship is supported by findings that vitamin D is involved in axonal growth[4], brain 
calcium metabolism[5], and brain cell differentiation[6]. In addition, vitamin D has been 
shown to stimulate phagocytosis and clearance of amyloid-β in the brain, one of the primary 
hallmarks of Alzheimer’s disease[7]. In accordance with these possible biological pathways, 
research has indicated that lower vitamin D levels are associated with a greater risk of 
developing Alzheimer’s disease and all-cause dementia[8]. However, evidence from both 
animal and human behavioural studies towards the role of vitamin D on cognition has been 
inconsistent. To date, over thirty cross-sectional studies have investigated the association 
between cognitive functions and 25-hydroxyvitamin D [25(OH)D], the main measure of 
vitamin D status. Most but not all of these studies reported a positive relationship between 
25(OH)D and cognition[9,10]. However, research in this field has been criticised for 
insufficient adjustment for confounding variables, small sample sizes, and the use of 
suboptimal methods for measuring 25(OH)D levels[11]. Moreover, prospective studies have 
reported mixed results regarding vitamin D and cognitive decline. Although four longitudinal 
studies have shown a significant association between lower vitamin D levels and declines in 
global cognition[12-15], and/or specific domains such as executive function[12] and 
attention[15], three major investigations were unable to find any association[16-18]. There is 
some evidence to suggest that the effects of vitamin D on cognition are gender-specific, with 
two studies finding more pronounced associations in women than in men[19,20]. It therefore 
remains to be determined whether vitamin D affects cognitive change over time in men, and 
many researchers have called for the development of more well-designed prospective studies 
on the relationship between vitamin D status and cognitive decline[21,22].  
 The European Male Ageing Study (EMAS) is a multi-centre population cohort study 
which assessed changes in physical and cognitive functioning of a large group of middle-aged 
and elderly men over a period of 4.4 years[23]. Cross-sectional analyses of the baseline 
measurements indicated that 25(OH)D levels were positively associated with cognitive 
processing speed in this cohort. In addition, it was found that the impact of vitamin D on 
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cognition may be more pronounced in individuals with 25(OH)D levels below 35 nmol/l and 
men over the age of 60[24]. In the present study we aim to investigate whether vitamin D 
status can predict cognitive decline using longitudinal data from EMAS. Secondly, it is our 
objective to examine a potential interaction between age and vitamin D on cognitive function. 
Nearly all of the previous longitudinal studies have focused on adults aged 65 and over[12-
16,18]. The one study that involved participants in late middle age (45-65 years) found no 
association between 25(OH)D levels and cognitive decline or risk of dementia[17]. It is 
therefore possible that maintaining an optimal vitamin D level is particularly important for 
older adults. As the current study includes elderly as well as middle-aged men, we are able to 
compare the effects of vitamin D deficiency on cognition across a wide age range. Finally, a 
unique feature of this study is that levels of 1,25-dihydroxyvitamin D [1,25(OH)2D], the 
active metabolite of 25(OH)D, were also analysed. This is the first study to examine 
1,25(OH)2D as a potential marker of cognitive decline. 
METHODS  
Participants  
Participant recruitment, study design and assessments of the European Male Ageing Study 
have previously been described in detail[23]. Briefly, 8,416 community-dwelling men aged 
40 to 79 years were invited to attend a screening at a local clinic. A short questionnaire was 
used to gather information on sociodemographic, general health, and lifestyle factors. The 
3,369 men who agreed to participate subsequently visited a research clinic to complete several 
interviewer-assisted questionnaires and undergo physical and cognitive assessments. The 
participating centres were based in Leuven, Belgium; Manchester, UK; Florence, Italy; Lodz, 
Poland; Malmö, Sweden; Santiago de Compostela, Spain; Szeged, Hungary; and Tartu, 
Estonia. Baseline measurements were carried out between 2003 and 2005, with follow-up 
testing taking place between 2007 and 2009. The average (SD) time between the two 
assessments was 4.4 (0.3) years. Of the men who took part in the baseline assessments, 2,736 
(86.1% of survivors) returned for Phase II testing. Of the other participants, 193 (5.7%) had 
died and 440 (13.1%) were lost to follow-up. Ethical approval was obtained in agreement 
with local constitutional requirements. Written informed consent was given by all the 
participants.  
Assessments 
Demographic information and details on co-morbidities, smoking, and alcohol consumption 
were collected using the postal questionnaire. The interviewer-assisted questionnaire included 
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questions about general health, the Physical Activity Scale for the Elderly[25] (PASE), and 
Beck’s Depression Inventory II[26] (BDI) to assess the presence and severity of depressive 
symptoms. Reuben’s Physical Performance Test[27] (PPT) was employed to measure 
physical function. Information on prescription and non-prescription medications was obtained 
by self-report. 
Tests of cognitive function  
Cognitive testing was carried out at baseline and during follow-up assessments. The EMAS 
cognitive test battery consisted of tasks measuring components of fluid intelligence. Tests 
were specifically selected for minimal cultural and linguistic influences and were standardised 
across centres. The cognitive tasks used were (in order of administration): the Rey-Osterrieth 
Complex Figure (ROCF) Copy and Recall tests, the Camden Topographical Recognition 
Memory (CTRM) test, and the Digit Symbol Substitution Test (DSST). Higher scores on each 
test reflect better cognitive performance of the participant.     
 In the ROCF Copy task, participants are required to copy an abstract two-dimensional 
figure as accurately as possible within five minutes. This test provides an indication of 
executive functioning and overall visuo-constructional ability[28]. In the ROCF Recall 
component, participants are asked unexpectedly to draw the figure from memory thirty 
minutes after completing the Copy task. In addition to visuo-constructional skills, this task 
taps into visual memory abilities. The ROCF scoring criteria used in this study are based on 
Osterrieth’s original test procedure, with a maximum score of 36 for both the Copy and Recall 
subtests. The CTRM was used to assess visual recognition memory[29] and involves the 
presentation of photographs of urban scenes followed by a forced-choice recognition 
component. Each correctly identified image is awarded with one point, with a maximum score 
of 30. Finally, cognitive processing speed and visual scanning were measured using the 
DSST[30,31]. In this timed paper-and-pencil subtest from the Wechsler Adult Intelligence 
Scale III, participants are asked to substitute as many symbols for digits as possible within 60 
seconds using a coding table. 
25(OH)D and 1,25(OH)2D assays  
In the baseline phase, morning phlebotomy was performed before 10 AM to obtain a fasting 
blood sample from all participants. Once processed, the serum was stored at -80ºC and 
shipped on dry ice to a central laboratory in Leuven, Belgium. A radio-immunoassay kit was 
used to determine total serum 25(OH)D levels (RIA kit; DiaSorin, Stillwater, MN, USA). 
Intra- and interassay coefficients for 25(OH)D levels were 11% and 9%, respectively. 
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1,25(OH)2D concentration was measured using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Detailed methodology of the 1,25(OH)2D measurements has 
previously been described by Vanderschueren and colleagues[32].  
Analyses 
The data were analysed using the statistical programme Stata version 13.1 (StataCorp LP, 
College Station, TX, USA). Participants with missing cognitive and/or 25(OH)D data were 
excluded from the analyses. Continuous cognitive decline on the ROCF Copy and Recall, 
CTRM, and DSST was analysed as a continuous as well as a categorical variable to allow for 
a possible non-linear association with cognitive decline as suggested by previous 
studies[10,19]. There is no established cut-off value for defining vitamin D deficiency in 
relation to cognition, leading to different 25(OH)D deficiency thresholds being used in studies 
of cognitive function. This heterogeneity in definitions of vitamin D sufficiency has made it 
difficult to compare results from different studies in the past. Following recommendations 
from Annweiler and colleagues[22], we looked at three of the commonly used thresholds. 
25(OH)D was classified as deficient (<25 nmol/l), insufficient (25-49 nmol/l), suboptimal 
(50-74 nmol/l) and sufficient (≥75 nmol/l). 1,25(OH)2D concentration was examined as a 
continuous variable. For the covariates, age (years), age left education (years), BMI (kg/m2), 
BDI score, PASE score, and PPT rating were analysed as continuous variables. Centre, 
tobacco use (currently smoking vs. non-smoking), alcohol consumption (≥1 day/week vs. <1 
day/week), co-morbidities (0,1, or ≥2), and season at which the blood test was taken at 
baseline (winter (Jan-March), spring (April-June), summer (July-Sept), and autumn (Oct-
Dec)) were included as categorical variables.       
 The associations between 25(OH)D level and cognitive decline were initially 
evaluated graphically using the Locally Weighted Scatterplot Smoothing (LOWESS) 
technique[33]. As this outlier-resistant method makes no assumptions about the form of the 
relationship, the resulting regression lines can provide information about non-linear 
associations between variables. Age-adjusted multiple linear regressions were then performed 
with continuous decline on all four cognitive tests as the outcome variables and continuous 
25(OH)D, categories of 25(OH)D, or continuous 1,25(OH)2D at baseline as the predictor. 
Subsequently, models were fitted with further adjustments for education, physical activity and 
performance, depression, co-morbidities, and lifestyle factors. Interaction terms between age 
by decade and 25(OH)D or 1,25(OH)2D level were added to the full models to assess 
differences across age groups in the relationship between cognitive decline and vitamin D 
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status. Finally, participants taking vitamin D and/or calcium supplements at baseline were 
excluded and the above analyses repeated using the remaining sample. 
RESULTS 
Subjects 
Of the 2,736 men returning for follow-up assessments, 105 participants were excluded from 
the analyses due to missing 25(OH)D measurements. Two participants with 25(OH)D levels 
above 250 nmol/l were removed from the dataset, as these values are higher than the upper 
limit of the normal range[34]. A total of 199 participants with missing CTRM and DSST data 
and 527 participants with missing ROCF data were omitted, leaving a sample of 2,430 men in 
the CTRM and DSST analyses and 2,102 men in the ROCF Copy and Recall models. For the 
1,25-dihydroxyvitamin D analyses, 408 men with missing 1,25(OH)2D information, 190 men 
with missing CTRM and DSST scores, and 517 men with missing ROCF scores were 
excluded. The final sample consisted of 2,138 participants in the CTRM and DSST analyses 
and 1,811 participants in the ROCF analyses. Baseline characteristics of the participants are 
listed in Table 1. Overall, the mean age of the study population (N = 2,430) was 59.0 years, 
average BMI was 27.6, and 41.9% of the participants had one or more co-morbidities. 
Cognition and vitamin D status in EMAS  
The mean cognitive scores at baseline are shown in Table 1. Independent t-tests indicated that 
participants who returned for follow-up measurements had higher cognitive scores than those 
who were lost to follow-up (all p <0.001). Linear regressions showed that older age, fewer 
years of education, higher scores on Beck’s Depression Inventory, lower physical activity and 
performance, and smoking were associated with greater decline on one or more cognitive 
tasks in the study sample (Table 2). Kruskal-Wallis tests revealed that change on all four 
cognitive test scores over time differed significantly between the centres (all p <0.001). 
 The average (SD) baseline 25(OH)D concentration was 64.4 (32.0) nmol/l and mean 
serum 1,25(OH)2D was 59.6 (16.6) pmol/l. Deficient, insufficient, and suboptimal vitamin D 
levels were common in this population with only 31.0% of all participants having sufficient 
25(OH)D concentrations. Men with low 25(OH)D levels tended to have a higher BMI, show 
more depressive symptoms, have lower physical activity and performance scores, be more 
likely to smoke, consume alcohol less than 1 day a week, and have more co-morbidities 
(Table 2). Kruskal-Wallis tests were conducted to assess 25(OH)D and 1,25(OH)2D by season 
and geographical region. 25(OH)D levels were significantly associated with season of 
measurement (H(3) = 368.74, p <0.001), as were 1,25(OH)2D concentrations (H(3) = 57.1, p 
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<0.001). Furthermore, both mean serum 25(OH)D level (H(7) = 268.69, p <0.001) and 
1,25(OH)2D level (H(7) – 226.91, p <0.001) varied significantly by centre. The highest levels 
of 25(OH)D were observed in Belgium (76.8 nmol/l), and lowest concentrations were found 
in Estonia (47.8 nmol/l). 
Table 1 Baseline characteristics of the EMAS participants included in the analyses (n = 2,430) 
Variable Mean (SD) or % 
Age (years) 59.0 (10.6) 
Age left education (years) 21.0 (7.4) 
BDI score 6.5 (6.0) 
PASE score 201.9 (88.9) 
PPT score 24.2 (2.4) 
BMI (kg/m2) 27.6 (4.0) 
Current smoker (%) 19.8 
Alcohol consumption ≥1 day/week (%) 58.0 
Vitamin D and/or calcium supplementation (%) 0.5 
Co-morbidities (%)  
    No co-morbidities  58.2 
    1 co-morbidity 26.1 
    ≥ 2 co-morbidities 15.8 
Cognitive tests  
    ROCF Copy score 33.8 (3.9) 
    ROCF Recall score 17.6 (6.4) 
    CTRM score 23.1 (4.5) 
    DSST score 28.7 (8.3) 
25(OH)D status (%)  
    Deficient (<25 nmol/l) 6.5 
    Insufficient (25 – 49 nmol/l) 31.1 
    Suboptimal (50 – 74 nmol/l) 31.4 
    Sufficient (≥75 nmol/l) 31.0 
Abbreviations: BDI, Beck’s Depression Inventory; PASE, Physical Activity Scale for the Elderly; PPT, Physical 
Performance Test; BMI, Body Mass Index; 25(OH)D, 25-hydroxyvitamin D; SD, Standard Deviation 
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Table 2 Determinants of both cognitive decline and baseline vitamin D levels: linear regression analysesƚ 
Baseline  
characteristics 
ROCF Copy 
change score 
ROCF Recall  
change score 
CTRM 
change score 
DSST 
change score 
Baseline 25(OH)D  
level (nmol/l) 
Baseline 1,25(OH)2D 
level (pmol/l) 
 β-coefficient (95% CI)      
Age (years) -0.018 (-0.033; -0.004)*  -0.049 (-0.072; -0.026)* -0.011 (-0.026; 0.003) -0.048 (-0.077; -0.031)* 0.084 (-0.035; 0.202) -0.058 (-0.123; 0.006) 
Age left education 
(years) 
0.023 (0.002; 0.044)* 0.021 (-0.013; 0.054) -0.002 (-0.022; 0.019) -0.016 (-0.042; 0.010) -0.162 (-0.333; 0.009) -0.049 (-0.143; 0.046) 
BDI score -0.028 (-0.053; -0.003)* 0.004 (-0.037; 0.044) -0.017 (-0.042; 0.008) -0.038  (-0.069; -0.006)* -0.771 (-0.978; -0.564)* 0.055 (-0.060; 0.170) 
BMI (kg/m2) 0.029 (-0.009; 0.068) 0.036 (-0.025; 0.098) -0.033 (-0.071; 0.004) -0.041 (-0.089; 0.007) -0.986 (-1.300; -0.672)* -0.321 (-0.491; -0.150)* 
PASE score -0.000 (-0.002; 0.002) 0.005 (0.002; 0.008)* -0.000 (-0.002; 0.002) 0.000 (-0.002; 0.002) 0.029 (0.013; 0.045)* 0.015 (0.006; 0.024)* 
PPT rating 0.149 (0.080; 0.218)* 0.284 (0.174; 0.394)* 0.006 (-0.060; 0.073) -0.080 (-0.16; 0.005) 1.29 (0.729; 1.843)* -0.252 (-0.555; 0.051) 
Current smoker       
    No Reference Reference Reference Reference Reference Reference 
    Yes 0.007 (-0.395; 0.409) -0.648 (-1.287; -0.008)* 0.249 (-0.133; 0.631) -0.070 (-0.554; 0.414) -9.981 (-13.171; -6.791)* -2.392 (-4.140; -0.645)* 
Alcohol 
consumption  
      
    <1 day/week Reference Reference Reference Reference Reference Reference 
    ≥1 day/week 0.039 (-0.277; 0.355) -0.072 (-0.575; 0.431) -0.001 (-0.306; 0.303) 0.232 (-0.154; 0.619) 9.058 (6.529; 11.586)* 1.905 (0.516; 3.293) 
Co-morbidities       
   No co- 
morbidities 
Reference Reference Reference Reference Reference Reference 
   1 co-morbidity 0.120 (-0.264; 0.503) 0.362 (-0.248; 0.973) -0.045 (-0.414; 0.324) -0.125 (-0.592; 0.343) -2.672 (-5.754; 0.411) 0.337 (-1.350; 2.025) 
   ≥2 co-
morbidities 
-0.024 (-0.488; 0.439) 0.161 (-0.577; 0.899) -0.125 (-0.583; 0.332) -0.550 (-1.131; 0.030) -6.809 (-10.634; -2.984)* -1.993 (-4.076; 0.089) 
* p < .05   
ƚ Age-adjusted where applicable   
Abbreviations: BDI, Beck’s Depression Inventory; BMI, Body Mass Index; PASE, Physical Activity Scale for the Elderly; PPT, Physical Performance Test; ROCF, Rey-Osterrieth 
Complex Figure; CTRM, Camden Topographical Recognition Memory; DSST, Digit Symbol Substitution Test; 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-
dihydroxyvitamin D   
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25(OH)D, 1,25(OH)2D and cognitive decline  
Age-adjusted LOWESS plots revealed no clear associations between 25(OH)D level at 
baseline and cognitive decline on the four tasks (see Figure 1). Results from the multiple 
linear regression models exploring the relationship between continuous 25(OH)D and 
cognitive decline are displayed in Table 3. In age-adjusted models, higher 25(OH)D 
concentrations were associated with a smaller decline in DSST performance over time. 
However, this association was not maintained when models were fully adjusted for covariates. 
Age-adjusted multiple regression analyses of categorical 25(OH)D status indicated that 
participants with vitamin D deficiency showed a greater decline on the DSST than 
participants with sufficient vitamin D levels. In addition, vitamin D insufficiency was 
associated with greater cognitive decline on the CTRM compared with sufficient vitamin D 
status. Both associations again disappeared when models were adjusted for additional 
covariates (see Table 4). There were no significant associations between 1,25(OH)2D and 
cognitive decline in either age-adjusted or fully adjusted models (Table 3). There was no 
evidence for a significant interaction between 25(OH)D or 1,25(OH)2D level and age in any 
of the models (all p >0.05). The results were unchanged when participants reporting vitamin 
D or calcium supplements intake were excluded from the regression analyses.           
 
Figure 1 Age-adjusted LOWESS plots of cognitive decline and 25(OH)D level.  
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Table 3 Linear regression models for baseline 25(OH)D level, baseline 1,25(OH)2D level, and 
decline in cognitive scores 
Model ROCF Copy ROCF Recall CTRM DSST 
                                                  β-coefficient (95% CI)    
25(OH)D     
   Model 1a -0.001 (-0.005; 
0.004) 
-0.005 (-0.013; 
0.003) 
-0.003 (-0.002; 
0.008) 
0.007 (0.001; 
0.013)* 
   Model 2b 0.001 (-0.007; 
0.008) 
-0.010 (-0.021; 
0.001) 
0.004 (-0.003; 
0.011) 
0.003 (-0.007; 
0.012) 
1,25(OH)2D     
   Model 1a -0.002 (-0.012; 
0.009) 
0.012 (-0.004; 
0.028) 
-0.007 (-0.017; 
0.003) 
0.005 (-0.008; 
0.017) 
   Model 2b 0.005 (-0.007; 
0.017) 
0.010 (-0.008; 
0.028) 
-0.009 (-0.020; 
0.003) 
0.009 (-0.004; 
0.023) 
*p <0.05 
aAdjusted for age 
bAdjusted for age, education, co-morbidities, centre, season, depressive symptoms, and lifestyle factors  
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; ROCF, Rey-Osterrieth 
Complex Figure; CTRM, Camden Topographical Recognition Memory; DSST, Digit Symbol Substitution Test 
Table 4 Linear regression models for baseline categorical 25(OH)D status and decline in 
cognitive scores 
 Deficient 
(N = 157) 
Insufficient  
(N = 755) 
Suboptimum 
(N = 764) 
Sufficient  
(N = 754) 
                                                β-coefficient (95% CI)    
Model 1a     
ROCF Copy 0.10 (-0.59; 0.79) 0.12 (-0.28; 0.51) 0.12 (-0.28; 0.52) Reference 
ROCF Recall 0.61 (-0.48; 1.71) 0.48 (-0.14; 1.11) 0.35 (-0.27; 0.98) Reference 
CTRM 0.24 (-0.40; 0.89) -0.41 (-0.79; -0.03)* 0.00 (-0.37; 0.38) Reference 
DSST 0.84 (-1.66; -0.02)* -0.48 (-0.96; 0.04) -0.22 (-0.70; 0.26) Reference 
Model 2b     
ROCF Copy -0.04 (-0.82; 0.74) -0.21 (-0.68; 0.26) 0.00 (-0.43; 0.44) Reference 
ROCF Recall 0.90 (-0.31; 2.11) 0.21 (-0.51; 0.93) 0.08 (-0.60; 0.76) Reference 
CTRM 0.43 (-0.30; 1.16) -0.27 (-0.72; 0.18) 0.21 (-0.21; 0.62) Reference 
DSST -0.11 (-1.01; 0.80) -0.08 (-0.63; 0.48) -0.08 (-0.60; 0.43) Reference 
* p < 0.05   
a Adjusted for age  
b Adjusted for age, education, co-morbidities, centre, season, depressive symptoms, and lifestyle factors  
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ROCF, Rey-Osterrieth Complex Figure; CTRM, Camden 
Topographical Recognition Memory; DSST, Digit Symbol Substitution Test 
DISCUSSION 
In this multi-centre prospective study of middle-aged and elderly European men, we found no 
evidence for any association between vitamin D status and subsequent cognitive decline in 
several domains, including processing speed, visual memory, and executive functioning. 
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Contrary to our expectations, we found no interaction effects of age and 25(OH)D 
concentration on cognition. These results differ from our previous cross-sectional findings 
that indicated a positive association between 25(OH)D levels and processing speed, 
particularly in men over the age of 60 years [24]. Although decline on the DSST was 
associated with both continuous 25(OH)D level and deficient vitamin D status in the age-
adjusted models in the present analyses, this association was not maintained when fully 
adjusted for confounding variables. Similarly, the association between decline on the CTRM 
and insufficient 25(OH)D status was significant in age-adjusted but not fully adjusted models. 
No significant associations were found between 1,25(OH)2D and cognitive decline.  
 Our findings are consistent with results from the Osteoporotic Fractures in Men Study 
(MrOS), which suggested that slight associations between 25(OH)D and decline in global 
cognition or executive function over 4.6 years in elderly men were mainly caused by 
confounding variables such as educational level[18]. Previous studies with insufficient 
adjustment for covariates may therefore have overestimated the strength of the relationship 
between vitamin D and cognition. Another possibility is that the mixed findings of positive 
associations[12-15] and null results[16-18] in earlier longitudinal investigations are due to 
gender differences, as some studies have suggested that the beneficial cognitive effects of 
high vitamin D levels are more pronounced in women than in men[19,20]. This would explain 
the lack of significant findings in both EMAS and the MrOS cohort. However, a large-scale 
observational study of elderly women was also unable to find significant associations between 
vitamin D and cognitive decline over 6 years[16]. There is thus no conclusive evidence that 
vitamin D status affects cognition more in women than in men.    
 Alternatively, it could be argued that the testing interval of 4.4 years in the current 
study was too short to uncover small effects of 25(OH)D on cognitive deterioration. This 
especially concerns middle-aged participants, as they are less likely to demonstrate rapid and 
marked cognitive decline than older adults. Biological risk factors are sometimes present for a 
substantial period of time before they have an impact on cognition. For example, 
neurofibrillary tangles and senile plaques associated with Alzheimer’s disease start to 
accumulate around the age of thirty in some individuals[35] while clinical changes generally 
do not appear until old age. Similarly, it is possible that chronic vitamin D deficiency in 
midlife only leads to increased risk of cognitive decline several years or even decades later. 
As other longitudinal studies spanning three to five years did report a relationship between 
cognitive decline and serum 25(OH)D[13-15], however, we expected that the time frame of 
our investigation would have been sufficient to detect such associations. As our study sample 
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was relatively young, cognitive deterioration may have been smaller than in studies of elderly 
individuals, making it more difficult to detect associations with vitamin D levels. However, 
interaction terms for 25(OH)D or 1,25(OH)2D levels, age by decade, and cognition showed 
that even in the oldest age group (≥70 years) there was no significant relationship between 
vitamin D and cognitive decline. It is therefore improbable that the null findings are caused 
entirely by the young age of this population compared to other longitudinal studies. A final 
explanation may be that, although the tasks used here assessed a wide range of cognitive 
functions, other domains such as language skills are more strongly affected by vitamin D. 
Previous research, however, has found no association between vitamin D concentration and 
verbal memory[21] or verbal fluency[36], whereas executive function[12,14,37] and 
processing speed[24,37] were correlated with serum 25(OH)D levels in several studies. 
 Consistent with our results, there is at present little evidence from clinical studies that 
increasing vitamin D levels improves cognition. Although animal models have suggested that 
vitamin D supplementation has a positive effect on brain energy metabolism and cognitive 
decline[38], this finding has not yet been confirmed by clinical trials involving healthy human 
adults. A study of 128 young adults receiving daily capsules of 5000 IU vitamin D or placebo 
found no difference in cognitive functioning between the groups after 6 weeks of 
supplementation[39]. This study was possibly underpowered due to its small sample size and 
relatively short administration of supplements. However, another investigation of 4,142 older 
women also found that taking one tablet of 400 IU vitamin D and 1000 mg of calcium 
carbonate per day for 7.8 years did not lead to slower cognitive decline or lowered risk of 
dementia compared to a placebo[40]. In both studies, the majority of the participants had 
sufficient vitamin D levels at baseline. It is possible that clinical trials focusing on individuals 
with deficient vitamin D status at baseline would produce different results. Further 
investigations using vitamin D supplements without additional nutrients in diverse 
populations are therefore needed to conclusively determine the role of serum 25(OH)D in 
cognitive functioning. Nevertheless, our current findings suggest that an increase in vitamin D 
concentration is unlikely to affect cognitive decline with age.  
Strengths and weaknesses  
A main strength of the European Male Ageing Study is the broad range of multi-disciplinary 
data collected. Due to extensive physiological assessments we were able to adjust for multiple 
critical confounders such as education, general health, depression, and BMI. Furthermore, this 
is the first longitudinal study to include middle-aged as well as elderly men, which allowed us 
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to examine the effects of vitamin D across different age groups. In contrast with previous 
studies, we also used multiple thresholds to identify participants with deficient, insufficient, 
suboptimal, or sufficient vitamin D status. As there is not yet an established cut-off value for 
vitamin D deficiency with regards to cognition, investigations like the present one can provide 
valuable information for future clinical trials[22]. Finally, this is the first investigation of 
vitamin D and cognition to include measurements of 1,25(OH)2D. It is acknowledged that 
interpretations of the data are limited by the single measurement of vitamin D concentrations, 
as these may not reflect 25(OH)D status at Phase II. Finally, the ROCF Copy showed a 
ceiling effect and may lack sensitivity for assessing cognitive deterioration in this relatively 
healthy population. It is also probable that practice effects influenced performance on the 
ROCF Recall and CTRM in Phase II, leading to potential underestimations of cognitive 
decline. Repeated testing is not expected to have affected results on the DSST, however, as 
this task is only minimally if at all subject to learning effects.  
Conclusion 
In this cohort of middle-aged and older European men, we found no indication of a 
relationship between 25(OH)D or 1,25(OH)2D levels and cognitive decline. Weak 
associations between 25(OH)D and processing speed or visual memory were explained by 
other factors such as co-morbidities and adverse lifestyle factors. The current findings are in 
line with several prospective studies and human clinical trials that have failed to find 
associations between vitamin D and cognitive decline. Further studies of longer duration and 
including both genders may be needed to clarify the relationship between 25(OH)D status and 
cognition. Based on our results, however, vitamin D levels do not appear to be markedly 
associated with cognitive functioning in ageing men. 
 
 
 
 
 
 
 
14 
 
Author affiliations: 1Gerontology and Geriatrics, KU Leuven, Leuven, Belgium; 2Clinical & 
Cognitive Neurosciences, Institute of Brain, Behaviour and Mental Health, The University of 
Manchester, UK; 3Arthritis Research UK Centre for Epidemiology, Institute of Inflammation 
and Repair, The University of Manchester, Manchester, UK; 4NIHR Manchester 
Musculoskeletal Biomedical Research Unit, Central Manchester NHS Foundation Trust, 
Manchester Academic Health Science Centre, Manchester, UK; 5Department of Obstetrics, 
Gynaecology and Andrology, Albert Szent-György Medical University, Szeged, Hungary; 
6Department of Medicine, Instituto Salud Carlos III, Complejo Hospitalario Universitario de 
Santiago (CHUS); 7Andrology Research Unit; 8Endocrinology Unit, University of Florence, 
Florence, Italy; 9Sexual Medicine and Andrology Unit, Department of Experimental, Clinical, 
and Biomedical Sciences, University of Florence, Florence, Italy; 10Reproductive Medicine 
Centre, Skåne University Hospital, University of Lund, Lund, Sweden; 11School  of Social 
Sciences, Cathie Marsh Institute for Social Research, The University of Manchester, 
Manchester, UK; 12Department of Surgery and Cancer, Imperial College London, 
Hammersmith Campus, London, UK; 13Department of Andrology and Reproductive 
Endocrinology, Medical University of Łódź, Łódź, Poland; 14Department of Human Nutrition, 
University of Glasgow, Glasgow, UK; 15Andrology Unit, United Laboratories of Tartu 
University Clinics, Tartu, Estonia; 16School of Chemistry, Manchester Institute of 
Biotechnology, Manchester, UK; 17Department of Rehabilitation Sciences, KU Leuven, 
Heverlee, Belgium; 18Department of Cellular and Molecular Medicine, KU Leuven, Leuven, 
Belgium, 19Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium; 20The 
Endocrinology and Diabetes Research Group, Faculty of Medical and Human Sciences, 
Institute of Human Development, University of Manchester, Manchester, UK; 21Department 
of Andrology and Endocrinology, KU Leuven, Leuven, Belgium; 22Department of Clinical 
and Experimental Medicine, KU Leuven, Belgium. 
 
 
 
 
 
 
15 
 
REFERENCES  
1. Holick MF. Vitamin D deficiency. New  Engl J Med 2007;357:266-281. 
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and 
prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. 
J Clin Endocrinol Metab 2011;96:1911-1930. 
3. Kesby JP, Eyles DW, Burne TH, et al. The effects of vitamin D on brain development 
and adult brain function. Mol Cell Endocrinol 2011;347:121–127. 
4. Chabas JF, Alluin O, Rao G, et al. Vitamin D2 potentiates axon regeneration. J 
Neurotraum 2008;25:1247-1256. 
5. Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection 
in parallel with downregulation of L-type calcium channel expression in hippocampal 
neurons. J Neurosci 2001;21:98-108. 
6. Marini F, Bartoccini E, Cascianelli G, et al. Effect of 1α,25‐dihydroxyvitamin D3 in 
embryonic hippocampal cells. Hippocampus 2010;20:696-705. 
7. Mizwicki MT, Liu G, Fiala M, et al. 1α, 25-Dihydroxyvitamin D3 and resolvin D1 
retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's 
disease patients. J Alzheimers Dis 2013;34:155 - 170. 
8. Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and 
Alzheimer disease. Neurology 2014;83:920-928. 
9. Van der Schaft J, Koek HL, Dijkstra E, et al. The association between vitamin D and 
cognition: A systematic review. Ageing Res Rev 2013;12:1013–1023. 
10. Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition, and dementia: A 
systematic review and meta-analysis. Neurology 2012;79:1397-1405. 
11. Schlögl M, Holick MF. Vitamin D and neurocognitive function. Clin Interv Aging 
2014;9:559-568. 
12. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in 
elderly persons. Arch Intern Med 2010;170:1135-1141. 
13. Wilson VK, Houston DK, Kilpatrick L, et al. Relationship between 25-
hydroxyvitamin D and cognitive function in older adults. J Am Geriatr Soc 
2014;62:636-641. 
14. Slinin Y, Paudel M, Taylor BC, et al. Association between serum 25 (OH) vitamin D 
and the risk of cognitive decline in older women. J Gerontol A Biol Sci Med Sci 
2012;67:1092-1098. 
16 
 
15. Granic A, Hill TR, Kirkwood TBL, et al. Serum 25‐hydroxyvitamin D and cognitive 
decline in the very old: The Newcastle 85+ Study. Eur J Neurol 2015;22:106-e107. 
16. Bartali B, Devore E, Grodstein F, et al. Plasma vitamin D levels and cognitive 
function in aging women: The Nurses’ Health Study. J Nutr Health Aging 
2014;18:400 - 406. 
17. Schneider ALC, Lutsey PL, Alonso A, et al. Vitamin D and cognitive function and 
dementia risk in a biracial cohort: The ARIC Brain MRI Study. Eur J Neurol 
2014;21:1211-1218. 
18. Slinin Y, Paudel ML, Taylor BC, et al. 25-Hydroxyvitamin D levels and cognitive 
performance and decline in elderly men. Neurology 2010;74:33-41. 
19. Breitling LP, Perna L, Müller H, et al. Vitamin D and cognitive functioning in the 
elderly population in Germany. Exp Gerontol 2012;47:122–127. 
20. Seamans KM, Hill TR, Scully L, et al. Vitamin D status and measures of cognitive 
function in healthy older European adults. Eur J Clin Nutr 2010;64:1172-1178. 
21. McGrath J, Scragg R, Chant D, et al. No association between serum 25-
hydroxyvitamin D3 level and performance on psychometric tests in NHANES III. 
Neuroepidemiology 2006;29:49-54. 
22. Annweiler C, Beauchet O. Vitamin D in older adults: The need to specify standard 
values with respect to cognition. Front Aging Neurosci 2014;6. 
23. Lee DM, O'Neill TW, Pye SR, et al. The European Male Ageing Study (EMAS): 
Design, methods and recruitment. Int J Androl 2009;32:11-24. 
24. Lee DM, Tajar A, Ulubaev A, et al. Association between 25-hydroxyvitamin D levels 
and cognitive performance in middle-aged and older European men. J Neurol 
Neurosurg Psychiatry 2009;80:722-729. 
25. Washburn RA, Smith KW, Jette AM, et al. The Physical Activity Scale for the Elderly 
(PASE): Development and evaluation. J Clin Epidemiol 1993;46:153–162. 
26. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San 
Antonio, TX, USA: Psychological Corporation, 1996. 
27. Reuben DB, Siu AL. An objective measure of physical function of elderly outpatients: 
The Physical Performance Test. J Am Geriatr Soc 1990;38:1105 - 1112. 
28. Osterrieth PA. Le test de copie d’une figure complexe. Arch Psychol 1944;30:206-
356. 
29. Warrington EK. The Camden memory tests manual (Vol. 1): Psychology Press, 1996. 
30. Uiterwijk JM. WAIS-III-NL-V. Lisse, The Netherlands: Swets & Zeitlinger, 2001. 
17 
 
31. Joy S, Kaplan E, Fein D. Speed and memory in the WAIS-III Digit Symbol-Coding 
subtest across the adult lifespan. Arch Clin Neuropsychol 2004;19:759-767. 
32. Vanderschueren D, Pye SR, O’Neill TW, et al. Active vitamin D (1,25-
dihydroxyvitamin D) and bone health in middle-aged and elderly men: The European 
Male Ageing Study (EMAS). J Clin Endocrinol Metab 2013;98:995-1005. 
33. Cleveland WS. Robust locally weighted fitting and smoothing scatterplots. J Am Stat 
Assoc 1979;74:829-836. 
34. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-586S. 
35. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent accumulation of 
Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-657. 
36. Wilkins CH, Sheline YI, Roe CM, et al. Vitamin D deficiency is associated with low 
mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 
2006;14:1032-1040. 
37. Menant J, C., Close JCT, Delbaere K, et al. Relationships between serum vitamin D 
levels, neuromuscular and neuropsychological function and falls in older men and 
women. Osteoporos Int 2012;23:981 - 989. 
38. Briones TL, Darwish H. Decrease in age-related tau hyperphorylation and cognitive 
improvement following vitamin D supplementation are associated with modulation of 
brain energy metabolism and redox state. Neuroscience 2014;262:143-155. 
39. Dean AJ, Bellgrove MA, Hall T, et al. Effects of vitamin D supplementation on 
cognitive and emotional functioning in young adults: A randomised controlled trial. 
PLoS One 2011;6:e25966. 
40. Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin D supplementation 
and cognitive impairment in the women's health initiative. J Am Geriatr Soc 
2012;60:2197-2205. 
 
 
 
